ResMed Inc.
RMDStock
$202.76−21.21%52W
Market Cap$29.31B
P/E20.92x
Div yield1.21%
Beta0.76
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-29.46%
Price vs S&P 500 (4W)1.79%
VGM Score51.88
Market Capitalization$29.31B
P/E Ratio (Annual)20.92x
Indicated Dividend Yield (Annual)1.21%
Earnings Surprise History
Q3 262.86est. 2.82
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.68
3.69
3.64
3.60
Industry Peers — Surgical & Medical Instruments(141)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RMDResMed Inc. | C | B | D | $202.76 |
| SYKStryker Corporation | C | C | D | $331.20 |
| MMM3M Company | C | F | B | $161.77 |
| BSXBoston Scientific Corp. | C | B | F | $44.62 |
| MDLNMedline Inc. Class A common stock | C | D | D | $41.11 |
| BDXBecton, Dickinson and Co. | B | C | B | $159.93 |
| DXCMDexCom, Inc. | C | B | C | $77.98 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | $362.44 |
| SOLVSolventum Corporation | C | D | B | $81.70 |
| PENPenumbra, Inc. | F | C | B | $319.60 |
| BAXBaxter International Inc. | B | F | C | $23.35 |
About
ResMed is a global leader in respiratory care devices for sleep apnea treatment, with structural growth tailwinds from rising diagnoses, aging populations, and increasing obesity prevalence. The company generates approximately two-thirds of revenue from the Americas, with the remainder from Europe, Japan, and Australia. ResMed is building competitive differentiation through digital health platforms that deliver clinical data to patients, healthcare providers, and payers in out-of-hospital settings.